A Phase 3 interventional study of Levodopa-Carbidopa Intestinal Gel (LCIG) and CADD-Legacy® 1400 ambulatory infusion pump in Advanced Parkinson's Disease, sponsored by AbbVie. Completed at 61 sites in 11 countries. Open to participants aged 30 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-12-02.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Parkinson Disease by AbbVie — 6 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · AbbVie.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2009, is one of 16 in phase 3, and was the 4th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →6 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Croatia and 6 more countries
Ages 18–69
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in Spain
Ages 18+
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Germany
Ages 18–67
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 99 Years · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 262 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 63 across the 25 interventional studies, 131 across the 18 observational. Of the 33 that completed or were terminated, 18 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
5 of the studies in Parkinson Disease by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07284342AbbVieA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa | 2027-01 |
| NCT05916157AbbVieAn Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | 2027-01 |
| NCT06639620AbbVieStudy To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting | 2027-03 |
| NCT06965374AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease | 2027-06 |
| NCT07227896AbbVieReal-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Parkinson Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 [NCT00360568] or Study S187.3.004 [NCT00335153]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL. Participants will receive LCIG until it is commercially available.
Drug: Levodopa-Carbidopa Intestinal Gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
Also known as: Carbidopa-Levodopa Enteral Suspension (CLES), Duopa®, Duodopa®
Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
All participants previously had a PEG-J placed in one of the prior LCIG studies.
Number of Participants With Treatment-emergent Adverse Events
Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure. At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug. Serious AEs included any untoward medical occurrence that: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * was a congenital anomaly/birth defect The severity of all AEs was characterized as mild, moderate or severe according to the following definitions: * Mild: usually transient and do not interfere with daily activities. * Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities. * Severe: events interrupt the subject's usual daily activity.
Time frame: From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Number of Participants With Device Complications
Device complications include complications with the pump, intestinal tube, PEG-J or stoma.
Time frame: From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days.
Number of Participants With Sleep Attacks
Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event.
Time frame: Baseline (final assessment period of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Intense Impulsive Behavior
To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.
Time frame: Baseline (final assessment of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants Who Developed Melanoma
A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist.
Time frame: Once per year during the study; median duration of treatment was 1178 days.
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI)
Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available. * Procedure and device associated events * Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance * Weight loss * Cardiovascular fatalities * Respiratory tract aspiration including aspiration pneumonia/pneumonitis.
Time frame: From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Number of Participants With Any Suicidal Ideation or Behavior
The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation. Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors. The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.
Time frame: Every 6 months (beginning with implementation of Protocol Amendment 3) until final visit; median duration of treatment was 1178 days.
Number of Participants With Potentially Clinically Significant Vital Sign Values
A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.
Time frame: Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Potentially Clinically Significant Hematology Laboratory Values
A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.
Time frame: Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Potentially Clinically Significant Chemistry Laboratory Values
A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value. ULN = upper limit of normal
Time frame: Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Number of Participants With Vitamin Levels Outside of the Normal Range
Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid \[MMA\], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested.
Time frame: Every 6 months (beginning with implementation of Protocol Amendment 2) until final visit; median duration of treatment was 1178 days.
Number of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year
Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness. The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.
Time frame: Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10, > Year 10 (maximum time on treatment was approximately 11.5 years).
Change in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment
The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment
The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort. "On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment
The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias). The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Change in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment
The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease: * Mobility (e.g., fear of falling when walking) - 10 questions * Activities of daily living (e.g., difficulty cutting food) - 6 questions * Emotional well-being (e.g., feelings of isolation) - 6 questions * Stigma (e.g., social embarrassment) - 4 questions * Social support - 3 questions * Cognition - 4 questions * Communication - 3 questions * Bodily discomfort - 3 questions Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.
Time frame: Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Enrollment began in November 2009 and was completed in October 2012. Participants were enrolled at 61 sites in 11 countries: Australia, Canada, Czech Republic, Israel, New Zealand, Poland, Portugal, the Russian Federation, Thailand, the United Kingdom, and the United States.
| Milestone | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Started | 262 |
| Completed | 145 |
| Not completed | 117 |
| Withdrew: Adverse event | 84 |
| Withdrew: Lack of efficacy | 7 |
| Withdrew: Withdrawal by subject | 22 |
| Withdrew: Administrative | 2 |
| Withdrew: Protocol violation | 2 |
Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure. At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug. Serious AEs included any untoward medical occurrence that: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * was a congenital anomaly/birth defect The severity of all AEs was characterized as mild, moderate or severe according to the following definitions: * Mild: usually transient and do not interfere with daily activities. * Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities. * Severe: events interrupt the subject's usual daily activity.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Any treatment-emergent adverse event (TEAE) | 253 |
| TEAE at least possibly related to study drug | 219 |
| Serious TEAE | 159 |
| Severe TEAE | 152 |
| TEAE leading to premature study discontinuaton | 82 |
| TEAE leading to death | 58 |
Device complications include complications with the pump, intestinal tube, PEG-J or stoma.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Any device complication | 244 |
| Device complication leading to tube replacement | 183 |
| Device complication with associated adverse event | 177 |
| Device complication with associated adverse event leading to tube replacement | 43 |
Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Baseline: One or more sleep attacks | 6 |
| Baseline: One or more sleep attacks with a bad outcome | 0 |
| Post-baseline: One or more sleep attacks | 27 |
| Post-baseline: One or more sleep attacks with a bad outcome | 3 |
To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Baseline: Pathological Gambling | 1 |
| Baseline: Trichotillomania | 0 |
| Baseline: Kleptomania | 0 |
| Baseline: Pyromania | 0 |
| Baseline: Intermittent Explosive Disorder | 0 |
| Baseline: Compulsive Buying | 1 |
| Baseline: Compulsive Sexual Behavior | 1 |
| Post-baseline: Pathological Gambling | 1 |
| Post-baseline: Trichotillomania | 0 |
| Post-baseline: Kleptomania | 0 |
| Post-baseline: Pyromania | 0 |
| Post-baseline: Intermittent Explosive Disorder | 0 |
| Post-baseline: Compulsive Buying | 2 |
| Post-baseline: Compulsive Sexual Behavior | 14 |
A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Number of Participants Who Developed Melanoma | 2 |
Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available. * Procedure and device associated events * Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance * Weight loss * Cardiovascular fatalities * Respiratory tract aspiration including aspiration pneumonia/pneumonitis.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| TE AESI related to procedure and device | 162 |
| TE AESI related to polyneuropathy | 24 |
| TE AESI related to weight loss | 53 |
| TE AESI related to cardiovascular fatalities | 7 |
| TE AESI related to aspiration | 71 |
The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation. Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors. The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Any suicidal ideation or behavior | 32 |
| Any suicidal ideation | 30 |
| Any suicidal behavior | 6 |
| Non-suicidal self-injurious behavior | 1 |
A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Supine Systolic Blood Pressure ≥180 mmHg and > 40 mmHg increase from Baseline | 6 |
| Supine Systolic Blood Pressure ≤ 90 mmHg and > 30 mmHg decrease from Baseline | 13 |
| Standing Systolic Blood Pressure ≥ 180 mmHg and > 40 mmHg increase from Baseline | 1 |
| Standing Systolic Blood Pressure ≤ 90 mmHg and > 30 mmHg decrease from Baseline | 26 |
| Orthostatic Change in Systolic Blood Pressure Decrease of ≥ 30 mmHg | 73 |
| Supine Diastolic Blood Pressure ≥ 105 mmHg and > 30 mmHg increase from Baseline | 2 |
| Supine Diastolic Blood Pressure ≤ 50 mmHg and > 30 mmHg decrease from Baseline | 6 |
| Standing Diastolic Blood Pressure ≥ 105 mmHg and > 30 mmHg increase from Baseline | 7 |
| Standing Diastolic Blood Pressure ≤ 50 mmHg and > 30 mmHg decrease from Baseline | 14 |
| Orthostatic Change in Diastolic Blood Pressure Decrease of ≥ 20 mmHg | 45 |
| Supine Pulse ≥ 120 bpm and > 30 bpm increase from Baseline | 0 |
| Supine pulse ≤ 50 bpm and > 30 bpm decrease from Baseline | 3 |
| Standing pulse ≥ 120 bpm and > 30 bpm increase from Baseline | 5 |
| Standing pulse ≤ 50 bpm and > 30 bpm decrease from Baseline | 4 |
| Temperature ≥ 38.3℃ and ≥ 1.1℃ increase from Baseline | 0 |
| Weight ≥ 7% increase from Baseline | 36 |
| Weight ≥ 7% decrease from Baseline | 140 |
A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Red blood cells (RBC) < 2.0 × 10^12 cells/L (Female); < 2.5 × 10^12 cells/L (Male) | 0 |
| Haemoglobin < 90 g/L (Female); < 100 g/L (Male) | 9 |
| Haematocrit < 30% (Female); < 34% (Male) | 16 |
| White blood cells (WBC) < 2.8 × 10^9 cells/L | 3 |
| WBC > 16.0 × 10^9 cells/L | 2 |
| Absolute neutrophil count < 1.2 × 10^9 cells/L | 2 |
| Lymphocytes > 80% | 0 |
| Absolute lymphocyte count < 0.75 × 10^9 cells/L | 14 |
| Eosinophils > 10% | 4 |
| Monocytes > 30% | 1 |
| Platelet count < 95 × 10^9 cells/L | 2 |
| Platelet count > 700 × 10^9 cells/L | 0 |
| Mean corpuscular volume (MCV) < 60 fL | 0 |
| MCV > 120 fL | 0 |
A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value. ULN = upper limit of normal
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Creatinine > 177 µmol/L | 0 |
| Calcium < 1.75 mmol/L | 1 |
| Calcium > 3.0 mmol/L | 0 |
| Total bilirubin > 2 x ULN | 0 |
| Aspartate aminotransferase (AST) > 3 x ULN | 0 |
| Alanine aminotransferase (ALT) > 3 x ULN | 0 |
| Gamma glutamyl-transferase (GGT) > 3 x ULN | 5 |
| Lactate dehydrogenase (LDH) > 3 x ULN | 0 |
| Alkaline phosphatase (ALP) > 400 U/L | 0 |
| Creatine phosphokinase (CPK) > 3 x ULN | 6 |
| Non-fasting glucose < 2.78 mmol/L | 4 |
| Non-fasting glucose > 16.0 mmol/L | 1 |
| Uric acid > 500 µmol/L (Female); > 590 µmol/L (Male) | 0 |
| Blood urea nitrogen (BUN) > 10.8 mmol/L | 11 |
| Cholesterol > 12.9 mmol/L | 0 |
Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid \[MMA\], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested.
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Vitamin B12 < 148 pmol/L | 22 |
| Vitamin B12 > 775 pmol/L | 46 |
| Methylmalonic acid > 0.4 µmol/L | 65 |
| Homocysteine < 3.7 µmol/L | 1 |
| Homocysteine > 13.9 µmol/L | 198 |
| Vitamin B6 < 20 nmol/L | 155 |
| Vitamin B6 > 125 nmol/L | 108 |
| Folic acid < 4.5 nmol/L | 6 |
Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness. The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.
| Participants | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 | > Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No concomitant PD medications (LCIG only) | 126 | 107 | 96 | 74 | 52 | 38 | 33 | 28 | 21 | 17 | 8 |
| Concomitant oral levodopa/carbidopa | 100 | 91 | 74 | 55 | 37 | 16 | 9 | 8 | 5 | 4 | 1 |
| Other concomitant PD medications | 36 | 32 | 26 | 17 | 7 | 5 | 2 | 2 | 1 | 1 | 0 |
The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.
| hours | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | -3.97 ± 2.86 |
| Change from Baseline | -0.19 ± 2.19 |
The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort. "On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| hours | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | 3.86 ± 3.31 |
| Change from Baseline | -0.51 ± 3.19 |
The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia. "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement. The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| hours | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | 0.12 ± 3.03 |
| Change from Baseline | 0.70 ± 2.66 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| score on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | 1.51 ± 2.83 |
| Change from Baseline | 1.46 ± 2.29 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| score on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | 3.04 ± 7.76 |
| Change from Baseline | 6.11 ± 5.48 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| score on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | 4.51 ± 14.71 |
| Change from Baseline | 9.18 ± 10.63 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias). The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| score on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | 9.12 ± 20.91 |
| Change from Baseline | 16.82 ± 15.01 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias). The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| score on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | -2.27 ± 3.70 |
| Change from Baseline | 0.77 ± 2.86 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement. The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
| score on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change from initial LCIG infusion | -0.19 ± 2.55 |
| Change from Baseline | 0.55 ± 1.86 |
The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease: * Mobility (e.g., fear of falling when walking) - 10 questions * Activities of daily living (e.g., difficulty cutting food) - 6 questions * Emotional well-being (e.g., feelings of isolation) - 6 questions * Stigma (e.g., social embarrassment) - 4 questions * Social support - 3 questions * Cognition - 4 questions * Communication - 3 questions * Bodily discomfort - 3 questions Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.
| score on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Summary Index: Change from initial LCIG infusion | -1.46 ± 16.98 |
| Summary Index: Change from Baseline | 6.83 ± 13.14 |
| Mobility Domain: Change from initial LCIG infusion | -2.08 ± 27.98 |
| Mobility Domain: Change from Baseline | 12.01 ± 21.81 |
| Activities of Daily Living Domain: Change from initial LCIG infusion | -1.55 ± 28.40 |
| Activities of Daily Living Domain: Change from Baseline | 9.35 ± 20.40 |
| Emotional Well-Being Domain: Change from initial LCIG infusion | -0.58 ± 19.31 |
| Emotional Well-Being Domain: Change from Baseline | 2.53 ± 16.95 |
| Stigma Domain: Change from initial LCIG infusion | -9.50 ± 22.49 |
| Stigma Domain: Change from Baseline | -0.18 ± 19.52 |
| Social Support Domain: Change from initial LCIG infusion | 3.59 ± 19.54 |
| Social Support Domain: Change from Baseline | 2.25 ± 17.88 |
| Cognition Domain: Change from initial LCIG infusion | 1.78 ± 19.52 |
| Cognition Domain: Change from Baseline | 6.56 ± 19.63 |
| Communication Domain: Change from initial LCIG infusion | 3.19 ± 23.01 |
| Communication Domain: Change from Baseline | 8.17 ± 19.27 |
| Bodily Discomfort Domain: Change from initial LCIG infusion | -4.74 ± 24.61 |
| Bodily Discomfort Domain: Change from Baseline | 5.64 ± 19.70 |
Collected over From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, and maximum was 4217 days (11.5 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levodopa-Carbidopa Intestinal Gel | 59/262 (22.5%) | 159/262 (60.7%) | 223/262 (85.1%) |
| Event | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| PNEUMONIAInfections and infestations | 20/262 |
| COMPLICATION OF DEVICE INSERTIONGeneral disorders | 14/262 |
| DEATHGeneral disorders | 13/262 |
| FALLInjury, poisoning and procedural complications | 13/262 |
| POSTOPERATIVE WOUND INFECTIONInfections and infestations | 9/262 |
| PNEUMONIA ASPIRATIONRespiratory, thoracic and mediastinal disorders | 9/262 |
| WEIGHT DECREASEDInvestigations | 8/262 |
| PARKINSON'S DISEASENervous system disorders | 8/262 |
| DEVICE DISLOCATIONGeneral disorders | 6/262 |
| ANAEMIABlood and lymphatic system disorders | 5/262 |
| Event | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| VITAMIN B6 DECREASEDInvestigations | 71/262 |
| BLOOD HOMOCYSTEINE INCREASEDInvestigations | 59/262 |
| POSTOPERATIVE WOUND INFECTIONInfections and infestations | 55/262 |
| FALLInjury, poisoning and procedural complications | 47/262 |
| URINARY TRACT INFECTIONInfections and infestations | 45/262 |
| EXCESSIVE GRANULATION TISSUESkin and subcutaneous tissue disorders | 41/262 |
| INCISION SITE ERYTHEMAInjury, poisoning and procedural complications | 38/262 |
| PROCEDURAL SITE REACTIONInjury, poisoning and procedural complications | 33/262 |
| NAUSEAGastrointestinal disorders | 32/262 |
| WEIGHT DECREASEDInvestigations | 32/262 |
| Age, Continuous(years) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Mean | 64.1 ± 8.9 |
| Age, Customized(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| < 65 years | 133 |
| ≥ 65 years | 129 |
| Sex: Female, Male(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Female | 100 |
| Male | 162 |
| Ethnicity (NIH/OMB)(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 255 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 21 |
| Black of African Heritage or African American | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 239 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · www.abbvie.com
Ran from Nov 2009 to primary completion in Nov 2021, 144 months.
Results were first posted in Dec 2022, 1 year after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 144 months is above that.
Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.